Shares of Eris Lifesciences Ltd declined nearly 5% to ₹1,727 in early trade on Wednesday, August 6, even after the company posted a strong 41% year-on-year rise in consolidated net profit to ₹125 crore for Q1 FY26. The stock fell from its previous close of ₹1,808.10, as investors appeared to book profits after a sharp earnings surge.
The company reported a 7.4% year-on-year increase in consolidated revenue to ₹773 crore. Operating profit (EBITDA) rose 11% YoY to ₹277 crore, with margins improving by 106 basis points to 35.8%.
The domestic branded formulations (DBF) business was a key driver, growing 11% YoY—outpacing the Indian pharmaceutical market. The DBF margin improved by 155 basis points to 37%, supported by increased field strength and a better product mix. Eris noted that 12 of its top 25 mother brands now rank among the top five in their categories, with five brands crossing ₹100 crore in annual revenue.
Finance costs declined 20% due to faster debt repayment. The company also made progress in its insulin and GLP-1 portfolios, with production ramp-ups and new validations underway. Net debt stood at ₹2,317 crore as of June 30, 2025.
Despite strong fundamentals, the stock’s sharp decline reflects near-term volatility.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
